The 8 most recent market catalysts affecting $TRVI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 55
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28
Jones Trading analyst Debanjana Chatterjee maintained a 'Buy' rating on Trevi Therapeutics (TRVI) and raised the price target from $24 to $28. This action signals increased confide…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25
Oppenheimer analyst Leland Gershell maintained an 'Outperform' rating on Trevi Therapeutics (TRVI) and raised the price target from $24 to $25. This action signals continued bullis…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30
Cantor Fitzgerald analyst Josh Schimmer has maintained an 'Overweight' rating on Trevi Therapeutics (TRVI) and raised the price target from $25 to $30. This action signals continue…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 65
Trevi Therapeutics Q2 EPS $(0.11), Inline
Trevi Therapeutics announced its Q2 earnings per share, reporting a loss of $(0.11) per share. This figure met the consensus analyst estimate, which typically suggests a neutral ma…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 75
Trevi Therapeutics shares are trading higher after BMO Capital initiated its coverage on the stock with an Outperform rating and announced a price target of $36.
The initiation of coverage by a reputable investment bank like BMO Capital with an 'Outperform' rating and a $36 price target is a strong positive catalyst for Trevi Therapeutics (…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 65
BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36
BMO Capital's initiation of coverage on Trevi Therapeutics with an Outperform rating and a $36 price target is a significant event for the company. Analyst coverage can increase vi…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 60
B. Riley Securities Maintains Buy on Trevi Therapeutics, Raises Price Target to $31
This 8-K filing discloses that B. Riley Securities has maintained its 'Buy' rating on Trevi Therapeutics (TRVI) and significantly raised its price target from $21 to $31. This anal…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Trevi Therapeutics, Raises Price Target to $24
HC Wainwright & Co. analyst Brandon Folkes maintained a Buy rating on Trevi Therapeutics and raised the price target from $21 to $24. This action signals increased analyst confiden…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.